School of Medicine
Showing 1-10 of 87 Results
Rad/Molecular Imaging Scientist, Rad/Molecular Imaging Program at Stanford
Bio Research Focus and interests: Molecular Imaging, PET, Immuno-Oncology, Graft versus Host Disease, CAR T cells
Dr. Israt Alam is a Senior Scientist in the Radiology Department at Stanford University. She trained in Prof. Sanjiv Sam Gambhir's lab and transitioned to Dr. Michelle James' lab in 2020. Her research focuses on studying lymphocyte activation with the motivation of developing non-invasive imaging tools, to monitor immune dynamics in response to cancer immunotherapy and in immunopathology. Her work has supported the clinical translation of several nuclear imaging agents for early disease detection and prediction of treatment response. She has also worked on the development of several biomarker detection platforms for early disease detection.
-Senior Research Scientist, Department of Radiology, Stanford (2021-present)
-Life Sciences Research Associate, Department of Radiology, Stanford (2018-2021)
-Post-Doctoral Scholar, Department of Radiology, Stanford (2015-2018)
-Visiting Researcher under supervision of Prof. Spencer Shorte, Plateforme d'imagerie dynamique, Pasteur Institute, Paris (2014)
-Science Education Intern and Consultant: United Nations Educational, Science and Cultural Organization (UNESCO), Paris (2012-2013)
Physical Science Research Professional 1, Rad/Molecular Imaging Program at Stanford
Current Role at Stanford Ms. Azevedo focuses on the translation of radiotracers for imaging neurordegenerative diseases.
Vikram S Bajaj
Adjunct Professor, Rad/Molecular Imaging Program at Stanford
Bio Adj. Professor, Stanford Radiology.
Managing Director, Foresite Capital Management
Co-Founder/CEO, Foresite Labs
Chief Scientific Officer, GRAIL
Chief Scientific Officer and Co-Founder, Verily (Google Life Sciences)
Instructor, Radiology - Rad/Molecular Imaging Program at Stanford
Current Research and Scholarly Interests My current research areas of interest include developing new strategies for: 1) novel radioligand and radiotracer development for various targets involved in brain cancer, 2) preclinical animal models of glioblastoma, and 3) clinical translation of useful radiopharmaceuticals for early-detection of disease and monitoring therapy.